2017-10-26
Small
0personInquired
0personFavorited
ConnectType:
T - Technology & Patents
Industry:
Pharmaceuticals and Chemical IntermediatesFine Chemical Manufacturing
Country / Region:
China
Company Type:
Listed company
Registered Capital:
130 million RMB
Company Capability: Chemical Technology & Patents、Process Technology Development、Full-Cycle Chemical Project Services、Technology Transfer
BBChem Co.,Ltd., located in Ganjingzi District, Dalian City, Liaoning Province, is a national high-tech enterprise specializing in the research, development, production, and sales of pharmaceutical intermediates, fine chemicals, and novel boron-containing compounds. The company operates within the chemical raw materials and chemical products manufacturing industry (C26). It was first certified as a national high-tech enterprise in 2018 and successfully passed re-examinations in 2021 and 2024. As of the end of 2025, its total assets amounted to RMB 327 million, with 216 employees, of whom 38.9% are engaged in R&D.
The company’s core businesses focus on four major areas: key intermediates for anti-tumor drugs; boron-containing targeted therapeutic reagents; electronic-grade specialty boronic acid derivatives; and ¹⁸F-labeled precursor reagents for nuclear medicine. Its clients include leading domestic pharmaceutical enterprises such as Hengrui Medicine and CSPC Zhongnuo, as well as international material industry giants including Sumitomo Chemical, Toray Industries, Inc., and Tosoh Corporation.
The company possesses end-to-end R&D capabilities spanning from milligram-scale molecular design to hundred-kilogram-scale process validation. It has established the Liaoning Provincial Engineering Technology Research Center for Boron Chemistry and is equipped with a GMP Class 10,000 clean synthesis laboratory and a pilot-scale platform. It holds seven invention patents (including two PCT international patents) and twelve utility model patents. Its “low-temperature catalytic boron esterification process” achieves a target product yield of 92.3% and a total impurity level of ≤0.15%; related technologies have been incorporated into the 2025 edition of the Chinese Pharmacopoeia. The company has obtained certifications for ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018, holds a “Safety Production License for Hazardous Chemicals,” and has completed SIS+DCS automated control upgrades across all production facilities, which have passed provincial-level acceptance.
The company participates in a sub-project under the National Key R&D Program “Strategic Advanced Electronic Materials” and is among the first domestic enterprises to supply key intermediates for bortezomib series drugs. Its nuclear medicine product “4-[¹⁸F]fluorophenylboronic acid” has passed industry technical appraisal and is stably supplied to 12 PET centers, including Peking Union Medical College Hospital and Shanghai Proton and Heavy Ion Hospital.
Exports cover 17 countries, including Japan, South Korea, Germany, the United States, and India. In 2025, export revenue totaled USD 42.8 million, with exports to Japan and South Korea accounting for 53.7%. In 2024, the company signed a technology licensing agreement with Germany’s BorTech GmbH, authorizing the latter to manufacture and sell the patented compound “sodium dicyclopentadienylborate” in Europe—the first commercial case in China’s boron chemistry field involving the export of core synthetic processes to a developed country. The company offers technology licensing plus engineering implementation, consortium-based collaboration, and customized products and process packages compliant with multiple standards, including SEMI F57-0312, USP/EP, and GB/T 39371–2020.
Connect
More Suppliers科林能源技术(北京)有限公司
77
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp
凯铭科技(杭州)有限公司
79
0
T - Technology & Patents
P - Procurement
Dalian Pace Gas Equipment Co., Ltd.
114
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp





































